Announcements

Announcements

New York Times
Health
F.D.A. Official Under Bush Is Trump’s Choice to Lead Agency
By KATIE THOMAS
MARCH 10, 2017
President Trump said Friday that he intended to nominate Scott Gottlieb, a partner at a venture capital fund with longstanding ties to the pharmaceutical and biotech industries, to lead the Food and Drug Administration…

::::::

CEPI – Coalition for Epidemic Preparedness Innovations [to 11 March 2017]
http://cepi.net/
10 March 2017
CEPI Newsletter
Excerpt
More than 30 applications for CEPI’s first call
CEPI received more than 30 applications for our first call for development of vaccines against Lassa, MERS-COV and Nipah, which had deadline 8 March. The applications will now be evaluated, and shortlisted applicants will be invited to submit full proposals in April 2017.
The partner organizations represented among the applicants are from North America, Europe, Africa, the Middle East, South-East Asia and Australia, representing academic institutions, biotechs, large pharmaceutical companies and Product Development Partnerships. There was also a broad diversity displayed in the vaccine platform technologies being used, including novel concepts.

::::::

UNAIDS [to 11 March 2017]
http://www.unaids.org/
Press release
On International Women’s Day UNAIDS is urging countries to stop 1 million women and girls from becoming infected with HIV every year
Nearly 1 million women are becoming infected with HIV every year and only half of all women living with HIV have access to lifesaving treatment—making AIDS now the leading cause of death worldwide among women between the ages of 30 and 49.

GENEVA, 8 March 2017—On International Women’s Day UNAIDS has released a new report which shows that there is an urgent need to scale up HIV prevention and treatment services for women and girls. The report, When women lead, change happens, shows that globally in 2015, there were 18.6 million women and girls living with HIV, 1 million women and girls became newly infected with HIV and 470 000 women and girls died of AIDS-related illnesses.

“Women are leading change in increasing demand for and access to HIV and health services. This movement needs to grow to allow families to thrive, societies to flourish and economies to progress,” said Michel Sidibé, Executive Director of UNAIDS. “Women’s rights are human rights—no exceptions.”

The report shows that women are more vulnerable to HIV than men. Domestic violence and sexual abuse have been shown to increase the risk of HIV among women. Data show that in high HIV prevalence settings women who experience intimate partner violence are up to 50% more likely to acquire HIV.

A lack of access to education and health services and a lack of decision-making power are also contributing factors to women’s vulnerability to HIV. In only 30% of countries worldwide do equal numbers of girls and boys attend upper secondary school and in western and central Africa only a third of young women between the ages of 15 and 24 report having the final say in their own health care. In Botswana, every additional year of school has been shown to reduce the risk of HIV infection by 11.6% among girls.

“Structural, behavioural and biological factors are compounding the risk of HIV infection among women,” said Mr Sidibé. “Every girl should have the opportunity to stay in school, every young woman should have the decision-making power over her own sexual and reproductive health and all women and girls should be able to protect themselves against HIV.”…

::::::

EDCTP [to 11 March 2017]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials.
9 March 2017
PanACEA kicks off new clinical trials programme for TB-drug evaluation
The EDCTP-funded PanACEA consortium (Pan-African Consortium for the Evaluation of Antituberculosis Antibiotics) who were recently awarded their second EDCTP grant worth almost € 11.4 million (PanACEA2), held a kick-off meeting in Cape Town, South Africa from 7-8 March 2017. The German and Swiss governments will contribute direct co-funding to PanACEA2 to the amounts of almost 3 million euro and 336.000 euro, respectively. The meeting gathered 80 delegates from all beneficiaries of the grant to go over what will be tackled during the next 5 years. Senior Project Officer Dr Monique Surette attended the meeting on behalf of EDCTP.
The PanACEA2 programme aims to develop at least two promising TB-treatment regimens with sound prediction data for a successful phase III evaluation, and advance one new agent into phase IIB. It will take full advantage of state of the art technologies, including innovative trial designs, new microbiological markers of treatment response, pharmacokinetic-pharmacodynamic analyses and modelling techniques. As a result, drug development processes could be accelerated by several years. PanACEA2 trial activities will be conducted at 11 research sites in six countries (Gabon, Malawi, Mozambique, South Africa, Tanzania, and Uganda) in sub-Saharan Africa with integrated research capacity development…

::::::